Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Polymyositis Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

3 recruiting trials for Polymyositis. Eligibility criteria explained in plain English.

TrialFinderData lists 3 Polymyositis clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 1 / Phase 2 (2 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Yale University (1), Miltenyi Biomedicine GmbH (1), Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is anti-CD19 CAR T cell therapy (drug, 1 trial), followed by CAR T cell.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
3
Total Trials
3
Recruiting Now
0
Phase 3 Trials
3
Sponsors

Track Polymyositis trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04402086

Rheumatology Patient Registry and Biorepository

To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.

Sponsor: Yale UniversityEnrolling: 50001 location
RECRUITINGPhase 1 / Phase 2NCT06347718

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease

The investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered...

Sponsor: Miltenyi Biomedicine GmbHEnrolling: 241 location
RECRUITINGPhase 1 / Phase 2NCT06685042

Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

The CATARSIS study explores the use of anti-CD19 CAR T-cell therapy as a novel approach for treating refractory systemic autoimmune diseases, specifically SLE, SSc, DM/PM, and...

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCSEnrolling: 81 location

Frequently Asked Questions

There are currently 3 clinical trials for Polymyositis, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Polymyositis, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Polymyositis, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.